MGMT and glioblastoma: Predictive biomarkers such as promoter methylation status of the DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) was causally linked to enhanced vulnerability of GBM cells to DNA damage inducing agents such as temozolomide chemotherapy [20, 53].